Drug Research
Beactica announces glioblastoma research collaboration with Uppsala University and the DDD Platform at SciLifeLab
Beactica AB, the Swedish drug discovery company announced a new research collaboration with Uppsala University and the Drug Discovery and Development Platform at SciLifeLab to study the effects on brain cancer stem cells of specific small molecules under development...
Drug Research
InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery
InMed Pharmaceuticals, Inc. , a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies announced the filing of a provisional patent application in the United States. INM-085 as a cannabinoid-based topical therapy...
Drug Research
Aptar Pharma Partners with Kali Care to Develop Real-Time Medication Management Technology
Aptar Pharma and Kali Care have announced that they entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical trials. The combination of Aptar Pharma’s ophthalmic device expertise, and Kali Care’s ground-breaking...
Articles
Top Loading Autoclaves for Labs on a Budget
The QCS EV 100 litre top loading autoclave is among the most space-efficient sterilisers available and will appeal to lab managers for their superior loading capability. They easily accommodate the tallest flasks, fermentors, and bioreactors, but...
Articles
Establishing a high throughput screen of drug solubility in pharmaceutical excipients
At the discovery and early stages of drug development, the aim is to evaluate the pharmacology, pharmacokinetics and toxicology of a compound using a simple liquid formulation.
During this process, drugs must dissolve at a concentration high enough to allow...
Drug Research
Bristol-Myers NASH Drug Reduces Liver Fat In Midstage Study
Bristol-Myers Squibb Company announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) (F1-F3). ...
Drug Research
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read